ConductScience.org, home

Comparison · NCT04871711-c20877ff

Delgocitinib Cream 20 mg/g vs Cream Vehicle: Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 2

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Delgocitinib Cream 20 mg/g vs Cream Vehicle: Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 2. Trial comparisons, record NCT04871711-c20877ff. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04871711-c20877ff

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1550.1190.198wilson
Risk in group 20.06210.03410.111wilson
Risk difference, group 1 minus group 20.09270.03270.144newcombe hybrid score
Risk ratio, group 1 over group 22.491.34.78log
Odds ratio, group 1 over group 22.771.365.61log
Number needed to treat, for one more participant with the outcome on Delgocitinib Cream 20 mg/g than on Cream Vehicle10.86.9230.6from the risk difference interval

Groups2

Group 2 names the comparator: vehicle.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Delgocitinib Cream 20 mg/gTwice-daily topical application for 16 weeks \>~\> Delgocitinib cream: Cream for topical application50323OG000
Group 2Cream VehicleTwice-daily topical application for 16 weeks \>~\> Cream vehicle: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.10161OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 2
Description
The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component and will be evaluated among participants with a baseline HESD itch score (weekly average) ≥4 points.
Time frame
2 weeks
Population

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema
NCT number
NCT04871711
Phases
PHASE3
Conditions
Chronic Hand Eczema
Interventions
Delgocitinib cream, Cream vehicle
Lead sponsor
LEO Pharma
Results first posted
2024-09-23

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04871711-c20877ff